Press release: Uppsala,
"I would like to say a big thank you to everyone who subscribed and therby showed their confidence in Dicot and the exiting time we have ahead of us. A subscription rate of over 85% is a very good outcome in the current market climate. I would also like to thank our advisors for their support; Corpura Fondkommission and Advokatfirman Lindahl", comments
Through the exercise of the warrants, the number of shares in Dicot increases by 192,414,488 shares, from 625,147,346 shares to 817,561,834. The share capital increases by
Through the exercise of TO5, Dicot will receive approximately 16.5 MSEK before issue costs. There are no costs for guarantees as such agreements have not been concluded.
Exercised warrants TO5 have now been replaced with interim shares (IA) pending registration with the Swedish Companies Registration Office. Conversion of interim shares to ordinary shares is expected to take place around
In
Complete terms of the warrants are available at Dicot's homepage www.dicot.se.
Advisors
For further information, please contact
Phone: +46 72 502 1010 Phone: +46 76 109 0000
E-mail: elin.trampe@dicot.se E-mail: bjorn.petersson@dicot.se
About Dicot
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at
Dicot is listed on
This disclosure contains information that
https://news.cision.com/dicot-ab--publ-/r/dicot-s--warrants-of-series-to5-subscribed-at-85-4--provides-the-company-16-5-msek-before-cost,c3870358
https://mb.cision.com/Main/17172/3870358/2437874.pdf
(c) 2023 Cision. All rights reserved., source